IceCure Reports 26% Revenue Growth and Significant U.S. Sales Expansion in Q3 2026

IceCure (ICCM) reported a 26% increase in total revenue to $2.6 million for the first nine months of 2026, fueled by an 83% surge in U.S. sales. The company has significantly expanded its commercial footprint in the United States, growing from 11 states at the end of Q2 2025 to 21 states as of September 30, 2026. This growth is driven by increased physician adoption of the ProSense cryoablation system. Despite revenue gains, IceCure reported a net loss of $12.9 million for the nine-month period due to heavy investments in R&D and sales personnel. However, the company achieved key regulatory milestones, including authorization from China's National Medical Products Administration and an exclusive distribution agreement in the Netherlands. Management provided optimistic 2027 guidance, projecting double-digit revenue growth.

By Motley Fool Transcribing · Motley Fool ·

IceCure Reports 26% Revenue Growth and Significant U.S. Sales Expansion in Q3 2026

Topics: Clinical Trials International Expansion Operating Loss Regulatory Approval Revenue Growth

Read the full article at Motley Fool

More World news